Cumberland Partners’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$19.5M Sell
120,760
-1,074
-0.9% -$179K 1.28% 26
2026
Q2
$23.1M Sell
121,834
-23,912
-16% -$4.5M 1.5% 23
2026
Q1
$28.7M Buy
145,746
+83,040
+132% +$16M 2.18% 18
2025
Q4
$11.5M Buy
62,706
+125
+0.2% +$21.9K 0.71% 32
2025
Q3
$9.6M Sell
62,581
-75
-0.1% -$11.4K 0.63% 35
2025
Q2
$8.76M Sell
62,656
-16
-0% -$2.24K 0.61% 36
2025
Q1
$9.21M Buy
62,672
+60,366
+2,618% +$8.73M 0.71% 32
2024
Q4
$302K Buy
2,306
+107
+5% +$15K 0.02% 155
2024
Q3
$343K Buy
2,199
+116
+6% +$18.7K 0.02% 166
2024
Q2
$325K Sell
2,083
-622
-23% -$93.6K 0.02% 161
2024
Q1
$367K Buy
2,705
+32
+1% +$4.24K 0.03% 178
2023
Q4
$362K Hold
2,673
– – 0.03% 165
2023
Q3
$362K Hold
2,673
– – 0.03% 157
2023
Q2
$383K Sell
2,673
-50
-2% -$7.36K 0.04% 144
2023
Q1
$378K Hold
2,723
– – 0.04% 147
2022
Q4
$369K Sell
2,723
-575
-17% -$72.1K 0.04% 147
2022
Q3
$362K Hold
3,298
– – 0.04% 138
2022
Q2
$436K Buy
+3,298
New +$433K 0.04% 140

Other funds holding AZN

Cumberland Partners's AZN Position: Q3 2026 in Review

Cumberland Partners reduced its AstraZeneca (AZN) stake by 0.88% in Q3 2026, selling an estimated $179K and leaving 120,760 shares worth $19.5M. The position accounts for 1.28% of the portfolio, ranked #26.

Cumberland Partners first reported a position in AZN in Q2 2022 and has held it in 18 quarters since. The position peaked at $28.7M in Q1 2026. 1,441 funds tracked by Wall St. Rank hold AZN as of Q3 2026.

  • Cumberland Partners held 120,760 shares of AstraZeneca worth $19.5M as of Q3 2026.
  • Cumberland Partners sold 1,074 AstraZeneca shares in Q3 2026, an estimated $179K.
  • AstraZeneca made up 1.28% of Cumberland Partners's portfolio in Q3 2026, its #26 holding.
  • Cumberland Partners first reported a position in AstraZeneca in Q2 2022 and has held it in 18 quarters since.
  • Cumberland Partners's AstraZeneca position peaked at $28.7M in Q1 2026.
  • 1,441 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2026.

Based on Cumberland Partners's 13F filing for Q3 2026, filed 16 Nov 2026.